ArticleACS medicinal chemistry letters2011
Bioanalytical Screening of Riboflavin Antagonists for Targeted Drug Delivery - A Thermodynamic and Kinetic Study.
Article in ACS medicinal chemistry letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 27 citations in OpenAlex.
- Riboflavin-Targeted Drug Delivery.Cancers · 2020Review
- Atomic force microscopy probing of receptor-nanoparticle interactions for riboflavin receptor targeted gold-dendrimer nanocomposites.The journal of physical chemistry. B · 2014Article
- Avidity modulation of folate-targeted multivalent dendrimers for evaluating biophysical models of cancer targeting nanoparticles.ACS chemical biology · 2013Article
- Design and in vitro validation of multivalent dendrimer methotrexates as a folate-targeting anticancer therapeutic.Current pharmaceutical design · 2013Article
- Small Molecule Ligands For Active Targeting Of TrkC-expressing Tumor Cells.ACS medicinal chemistry letters · 2012Article
- Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic.Molecular pharmaceutics · 2012Article
- Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2012Article
- Biophysical characterization of a riboflavin-conjugated dendrimer platform for targeted drug delivery.Biomacromolecules · 2012Article
- Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.European journal of medicinal chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The present study screened riboflavin mimicking small molecules to determine their binding activity for the riboflavin binding protein. We performed thermodynamic and kinetic binding studies of these molecules using a combination of two analytical approaches; isothermal titration calorimetry and surface plasmon resonance spectroscopy. Screening of a biased set of non-riboflavin based small molecules by microcalorimetry led to the discovery of two known drug molecules, quinacrine and chloroquine, as favorable ligands for the riboflavin receptor with K(D) value of 264, and 2100 nM, respectively. We further demonstrated that quinacrine is a competitive ligand for the receptor as measured by surface plasmon resonance. Thus this study describes the identification of a novel class of dual acting riboflavin antagonists that target riboflavin receptor for cellular uptake and display multifunctional activities upon cellular entry.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.